![Marty J. Duvall](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Marty J.
Duvall currently works at Angiex, Inc., as Chief Executive Officer & Director from 2022.
Postes actifs de Marty J. Duvall
Sociétés | Poste | Début |
---|---|---|
Angiex, Inc.
![]() Angiex, Inc. Miscellaneous Commercial ServicesCommercial Services Angiex, Inc. operates as a biotechnology company, which engages in the development of an antibody-drug conjugate therapy for cancer. It focuses on TM4SF1, a membrane glycoprotein of tetraspanin topology that was originally discovered as a protein expressed on many human epithelial tumor cells. The company was founded by Paul Jaminet, Harold Dvorak, and Shou-Ching Jaminet in 2015 and is headquartered in Cambridge, MA. | Directeur Général | 22/06/2022 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
Angiex, Inc.
![]() Angiex, Inc. Miscellaneous Commercial ServicesCommercial Services Angiex, Inc. operates as a biotechnology company, which engages in the development of an antibody-drug conjugate therapy for cancer. It focuses on TM4SF1, a membrane glycoprotein of tetraspanin topology that was originally discovered as a protein expressed on many human epithelial tumor cells. The company was founded by Paul Jaminet, Harold Dvorak, and Shou-Ching Jaminet in 2015 and is headquartered in Cambridge, MA. | Commercial Services |